Jonathan Schechter
Director at PharmaCyte Biotech, Inc. (PMCB) since August 2022
Jonathan Schechter has filed 22 insider reports with the SEC since June 2021, as director at PharmaCyte Biotech, Inc. (PMCB), director at Oblong, Inc. (TWAV) and director at TAO Synergies Inc. (TAOX). In the last 12 months Jonathan Schechter bought $48.2K of stock on the open market. The latest filing, on July 17, 2026, reports other acquisition or disposition at PharmaCyte Biotech, Inc. (PMCB).
- Filings
- 22
- Companies
- 3
- Bought on market
- $108K
- Sold on market
- $23.7K
Companies where Jonathan Schechter is an insider
| Company | Role | Shares held | Bought | Sold | Avg buy | Price now | Last filing |
|---|---|---|---|---|---|---|---|
| Directorsince August 2022 | 192,500 | $48.2K | $0.80 | $5.42+578% | Jul 17, 2026 | ||
| Directorsince May 2023 | 25,000 | $59.9K | $2.40 | $1.17-51% | Nov 17, 2025 | ||
| Directorsince June 2021 | 14,035 | $23.7K | $1.87 | Oct 17, 2025 |
Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record. Price now: the latest daily close, against the average buy price.
Every filing
- Mar 31, 2026PMCBAmendment: SEC Form 4 filed by Director Schechter JonathanForm 4Other acquisition or disposition
- Mar 31, 2026PMCBSEC Form 4 filed by Schechter JonathanForm 4Grant or award
- Jan 7, 2026+$48.2KPMCBDirector Schechter Jonathan bought $48,232 worth of shares (60,000 units at $0.80), increasing direct ownership by 45% to 192,500 unitsForm 4Open-market purchase
- Dec 12, 2025PMCBDirector Schechter Jonathan was granted 150,000 shares and covered exercise/tax liability with 67,500 shares, increasing direct ownership by 165% to 132,500 unitsForm 4Grant or awardShares withheld for taxes or exercise price
- Nov 14, 2025+$19.1KTWAVDirector Schechter Jonathan bought $19,100 worth of shares (10,000 units at $1.91), increasing direct ownership by 67% to 25,000 unitsForm 4Open-market purchase
- Aug 6, 2025TAOXSEC Form 4 filed by Director Schechter JonathanForm 4Grant or award
- Sep 17, 2025+$13.5KTWAVDirector Schechter Jonathan bought $13,476 worth of shares (5,000 units at $2.70), increasing direct ownership by 50% to 15,000 unitsForm 4Open-market purchase
- Sep 16, 2025+$27.3KTWAVDirector Schechter Jonathan bought $27,321 worth of shares (10,000 units at $2.73)Form 4Open-market purchase
- Jun 30, 2025TAOXDirector Schechter Jonathan was granted 21,575 shares and covered exercise/tax liability with 8,630 shares, increasing direct ownership by 1,188% to 14,035 unitsForm 4Grant or awardShares withheld for taxes or exercise price
- Apr 3, 2025TAOXSEC Form 4 filed by Director Schechter JonathanForm 4Grant or award
- Apr 30, 2024PMCBSEC Form 4 filed by Director Schechter JonathanForm 4Grant or award
- Apr 8, 2024TAOXSEC Form 4 filed by Schechter JonathanForm 4Grant or award
- Nov 20, 2023PMCBSEC Form 4 filed by Schechter JonathanForm 4Grant or award
- May 29, 2023TWAVJonathan Schechter became an insiderForm 3New insider
- Mar 29, 2023TAOXSEC Form 4 filed by Schechter JonathanForm 4Grant or award
- Dec 16, 2022-$23.7KTAOXSEC Form 4: Schechter Jonathan sold $23,731 worth of shares (20,250 units at $1.17) as part of a pre-agreed trading plan, decreasing direct ownership by 42% to 28,500 units (for withholding tax)Form 4Open-market sale10b5-1 plan
- Nov 15, 2022TAOXSEC Form 4 filed by Schechter JonathanForm 4Grant or award
- Aug 15, 2022PMCBSEC Form 3: New insider Schechter Jonathan claimed ownership of 50,000 sharesForm 3New insider
- Apr 5, 2022TAOXSEC Form 4 filed by Schechter Jonathan (Amendment)Form 4Other acquisition or disposition
- Apr 5, 2022TAOXSEC Form 4 filed by Schechter JonathanForm 4Grant or award
- Jun 4, 2021TAOXSEC Form 3: SCHECHTER JONATHAN claimed ownership of 3,750 units of Common Stock (Amendment)Form 3New insider
- Jun 4, 2021TAOXSEC Form 3: SCHECHTER JONATHAN claimed ownership of 2,500 units of Common StockForm 3New insider
Also sits on boards with
Officers and directors who share two or more companies with Jonathan Schechter.
Compare Jonathan Schechter with
- Jonathan Schechter vs Robert Weinstein3 shared
- Jonathan Schechter vs Joshua Silverman2 shared
- Jonathan Schechter vs William S. Singer1 shared
- Jonathan Schechter vs Robert Ephron1 shared
- Jonathan Schechter vs Bruce Bernstein1 shared
- Jonathan Schechter vs Wayne Remell Walker1 shared
Other insiders at the same companies
- William S. SingerTAOX
- Robert EphronTAOX
- Bruce BernsteinTAOX
- Wayne Remell WalkerPMCB
- Michael M AbecassisPMCB
- Alan J TuchmanTAOX
- Peter HolstTWAV
- Jason T AdelmanTWAV
Questions about Jonathan Schechter
- What is Jonathan Schechter's role at PharmaCyte Biotech, Inc.?
- Jonathan Schechter reports to the SEC as director at PharmaCyte Biotech, Inc. (PMCB), according to the latest filing on July 17, 2026. Jonathan Schechter has also filed as director at Oblong, Inc. (TWAV) and director at TAO Synergies Inc. (TAOX).
- How many shares does Jonathan Schechter own?
- After the latest filing that states it, Jonathan Schechter directly owned 192,500 shares of PharmaCyte Biotech, Inc. (PMCB), 25,000 shares of Oblong, Inc. (TWAV) and 14,035 shares of TAO Synergies Inc. (TAOX). Shares held through trusts, funds or family members are reported separately and are not counted here.
- Has Jonathan Schechter bought or sold stock recently?
- The most recent open-market purchase was on January 7, 2026: bought 60,000 shares of PharmaCyte Biotech, Inc. (PMCB) for $48.2K at an average of $0.80. The most recent open-market sale was on December 16, 2022: sold 20,250 shares of Synaptogenix, Inc. (TAOX) for $23.7K at an average of $1.17.
- How do I get alerts when Jonathan Schechter files?
- Follow Jonathan Schechter on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale.
From SEC Forms 3, 4, 5 and 144 filed by Jonathan Schechter (SEC CIK 0001619259). Totals count each trade once, skipping amendments whose original is on file, from Jun 15, 2021 on. View on SEC EDGAR